+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Genetic Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • PDF Icon


  • 144 Pages
  • September 2023
  • Region: Global
  • IMARC Group
  • ID: 5633295
The global genetic testing market size reached US$ 15.9 Billion in 2022. Looking forward, the publisher expects the market to reach US$ 29.0 Billion by 2028, exhibiting a growth rate (CAGR) of 10.37% during 2023-2028.

Genetic testing, or deoxyribonucleic acid (DNA) testing, refers to a medical technique that identifies changes in the chromosome structure or DNA sequence. It includes the collection and analysis of individual blood samples for examining the genetic condition and the chances of developing or passing various inherited disorders in laboratory settings. Genetic testing assists in providing accurate results regarding gene mutation, eliminating the need for unnecessary checkups, and making informed decisions to manage health. At present, genetic testing is commercially available in varying types, such as carrier, diagnostic, predictive, presymptomatic and prenatal testing.

Genetic Testing Market Trends:

The increasing prevalence of genetic and chronic disorders across the growth represents the key factor driving the genetic testing market growth. This is further supported by the implementation of numerous favorable initiatives undertaken by the government bodies and non-governmental organizations (NGOs) for sensitizing masses regarding genetic testing. In line with this, the extensive utilization of genetic testing in pharmacogenomics, or drug-gene testing for examining the response of the body against certain medicines after its interaction with inherited genes, is contributing as another growth-inducing factor. Additionally, the sudden outbreak of coronavirus disease (COVID-19) pandemic has led to the widespread adoption of virtual testing and the home testing kits for sample collection purposes, which, in turn, is contributing to the market growth. The tremendous technological advancements in genetic testing techniques along with the introduction of DTC-GT (Direct-to-consumer genetic testing) kits are further propelling the market growth. Other factors, such as rising investments in the research and development (R&D) activities in the field of medical science, along with the strategic collaboration amongst top players for launching advanced personalized genetic testing kits, are creating a positive outlook for the market.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each sub-segment of the global genetic testing market report, along with forecasts at the global, regional and country level from 2023-2028. The report has categorized the market based on type, technology and application.

Breakup by Type:

  • Predictive and Presymptomatic Testing
  • Carrier Testing
  • Prenatal and Newborn Testing
  • Diagnostic Testing
  • Pharmacogenomic Testing
  • Others

Breakup by Technology:

  • Cytogenetic Testing and Chromosome Analysis
  • Biochemical Testing
  • Molecular Testing
  • DNA Sequencing
  • Others

Breakup by Application:

  • Cancer Diagnosis
  • Genetic Disease Diagnosis
  • Cardiovascular Disease Diagnosis
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 23andme Inc., Ambry Genetics Corporation (Konica Minolta Healthcare Americas Inc.), Bio-RAD Laboratories Inc., Cepheid (Danaher Corporation), Eurofins Scientific, Illumina Inc., Invitae Corporation, Luminex Corporation (DiaSorin), Myriad Genetics Inc., QIAGEN, Quest Diagnostics and Thermo Fisher Scientific.

Key Questions Answered in This Report:

  • How has the global genetic testing market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global genetic testing market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the technology?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global genetic testing market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Genetic Testing Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Predictive and Presymptomatic Testing
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Carrier Testing
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Prenatal and Newborn Testing
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Diagnostic Testing
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Pharmacogenomic Testing
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast
7 Market Breakup by Technology
7.1 Cytogenetic Testing and Chromosome Analysis
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Biochemical Testing
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Molecular Testing
7.3.1 Market Trends
7.3.2 Key Segments DNA Sequencing Others
7.3.3 Market Forecast
8 Market Breakup by Application
8.1 Cancer Diagnosis
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Genetic Disease Diagnosis
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Cardiovascular Disease Diagnosis
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States Market Trends Market Forecast
9.1.2 Canada Market Trends Market Forecast
9.2 Asia-Pacific
9.2.1 China Market Trends Market Forecast
9.2.2 Japan Market Trends Market Forecast
9.2.3 India Market Trends Market Forecast
9.2.4 South Korea Market Trends Market Forecast
9.2.5 Australia Market Trends Market Forecast
9.2.6 Indonesia Market Trends Market Forecast
9.2.7 Others Market Trends Market Forecast
9.3 Europe
9.3.1 Germany Market Trends Market Forecast
9.3.2 France Market Trends Market Forecast
9.3.3 United Kingdom Market Trends Market Forecast
9.3.4 Italy Market Trends Market Forecast
9.3.5 Spain Market Trends Market Forecast
9.3.6 Russia Market Trends Market Forecast
9.3.7 Others Market Trends Market Forecast
9.4 Latin America
9.4.1 Brazil Market Trends Market Forecast
9.4.2 Mexico Market Trends Market Forecast
9.4.3 Others Market Trends Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 23andme Inc. Company Overview Product Portfolio
14.3.2 Ambry Genetics Corporation (Konica Minolta Healthcare Americas Inc.) Company Overview Product Portfolio
14.3.3 Bio-RAD Laboratories Inc. Company Overview Product Portfolio Financials SWOT Analysis
14.3.4 Cepheid (Danaher Corporation) Company Overview Product Portfolio SWOT Analysis
14.3.5 Eurofins Scientific Company Overview Product Portfolio Financials SWOT Analysis
14.3.6 Illumina Inc. Company Overview Product Portfolio Financials SWOT Analysis
14.3.7 Invitae Corporation Company Overview Product Portfolio Financials
14.3.8 Luminex Corporation (DiaSorin) Company Overview Product Portfolio SWOT Analysis
14.3.9 Myriad Genetics Inc. Company Overview Product Portfolio Financials SWOT Analysis
14.3.10 QIAGEN Company Overview Product Portfolio Financials SWOT Analysis
14.3.11 Quest Diagnostics Company Overview Product Portfolio Financials SWOT Analysis
14.3.12 Thermo Fisher Scientific Company Overview Product Portfolio Financials SWOT Analysis

Companies Mentioned

  • 23andme Inc.
  • Ambry Genetics Corporation (Konica Minolta Healthcare Americas Inc.)
  • Bio-RAD Laboratories Inc.
  • Cepheid (Danaher Corporation)
  • Eurofins Scientific
  • Illumina Inc.
  • Invitae Corporation
  • Luminex Corporation (DiaSorin)
  • Myriad Genetics Inc.
  • Quest Diagnostics
  • Thermo Fisher Scientific.



Table Information